Celldex Therapeutics’ (CLDX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Guggenheim lifted their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the stock a buy rating in a research report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Friday, March 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics presently has an average rating of Moderate Buy and a consensus target price of $66.00.

Celldex Therapeutics Stock Up 1.3 %

Shares of CLDX opened at $42.21 on Tuesday. The stock has a market capitalization of $2.36 billion, a P/E ratio of -14.51 and a beta of 1.60. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The firm has a fifty day simple moving average of $41.91 and a two-hundred day simple moving average of $37.00.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.19. The firm had revenue of $4.13 million during the quarter, compared to the consensus estimate of $1.20 million. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. Sell-side analysts expect that Celldex Therapeutics will post -2.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Teacher Retirement System of Texas grew its stake in Celldex Therapeutics by 4.8% in the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 522 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Celldex Therapeutics by 70.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 805 shares in the last quarter. New York State Common Retirement Fund lifted its position in Celldex Therapeutics by 3.6% during the 3rd quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 821 shares during the period. Swiss National Bank boosted its stake in Celldex Therapeutics by 1.0% during the third quarter. Swiss National Bank now owns 88,300 shares of the biopharmaceutical company’s stock worth $2,430,000 after acquiring an additional 900 shares in the last quarter. Finally, Fisher Asset Management LLC grew its holdings in Celldex Therapeutics by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock worth $852,000 after purchasing an additional 954 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.